QX004N / Qyuns Therap, Jiangsu Hansoh Pharma - LARVOL DELTA

Hansoh Pharma Announces Late-Breaking Presentation of Phase 2 Study on HS-20137 (Anti-IL-23p19 Antibody) in Moderate to Severe Psoriasis at AAD 2025 Annual Meeting (Hansoh Pharma Press Release) - P2 | N=160 | ChiCTR2300075645 | "A total of 159 subjects were enrolled in this study, and 156 completed the primary endpoint assessment. Eye-catching primary results: At week 16, PASI 75 and PASI 90 were achieved in 92.3% and 76.9% participants of 200mg Q8W group (NRI fill), respectively, and the proportion of participants achieving PASI 100 was up to 40% in the 200mg Q12W group.After week 16, proportion of patients achieved PASI 90 increased to 84.6%,89.7% and 87.2% at week 20,24 and 28 in 200mg Q8W group. Rapid response after first injection: HS-20137 had a rapid response, with PASI scores reduced from the baseline after the first injection, by more than 40% at week 4 and 70% by week 8. The mean PASI score decreased to below 3.3 by week 16 and continued to decline steadily, reaching below 3.0 by week 28."

Late-breaking abstract • P2 data • Psoriasis

Safety and Efficacy of Anti-IL-23 Monoclonal Antibody QX004N for Patients With Psoriasis: A Randomized Clinical Trial. (PubMed, JAMA Dermatol) - "In this randomized clinical trial, QX004N was well tolerated and demonstrated superior efficacy compared to placebo in patients with moderate to severe plaque psoriasis. Chinese Clinical Trial Registry Identifier: CTR20212313 and CTR20223457."

Clinical • Journal • Dermatology • Immunology • Psoriasis • IL23A